(Q53226586)

English

Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.

scientific article published in November 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17967843

Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17967843

relapsing-remitting multiple sclerosis

0 references

multiple sclerosis

0 references

Nikos Evangelou

1 reference

ORCID Public Data File 2021

author name string

K Baum

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17967843

C O'Leary

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17967843

F Coret Ferrer

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17967843

E Klímová

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17967843

L Procházková

5

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17967843

J Bugge

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17967843

BRIGHT Study Group

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17967843

publication date

1 November 2007

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17967843

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17967843

13

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17967843

9

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17967843

1153-1160

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17967843

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1177%2F1352458507079291

21 January 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1177%2F1352458507079291

21 January 2018

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

https://api.crossref.org/works/10.1177%2F1352458507079291

21 January 2018

Managing the adverse effects of interferon-beta therapy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458507079291

21 January 2018

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1177%2F1352458507079291

21 January 2018

Cutaneous ulcerations following subcutaneous interferon beta injection to a patient with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458507079291

21 January 2018

Local pain during REBIF injection is not due to acidic pH.

1 reference

https://api.crossref.org/works/10.1177%2F1352458507079291

21 January 2018

Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1177%2F1352458507079291

21 January 2018

Prevalence and impact of depression and pain in neurology outpatients

1 reference

https://api.crossref.org/works/10.1177%2F1352458507079291

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458507079291

21 January 2018

Identifiers

10.1177/1352458507079291

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17967843

release_rxvx3rdkh5b55lcalaahc3x2se

1 reference

https://api.fatcat.wiki/v0/release/rxvx3rdkh5b55lcalaahc3x2se

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/17967843

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53226586&oldid=1842862960"